(PharmaNewsWire.Com, July 29, 2020 ) The global overactive bladder treatment market is projected to reach USD 4.19 Billion by 2022 from USD 3.63 Billion in 2017, at a CAGR of 2.9% during the forecast period. This market is consolidated in nature with a few regional and national players. In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (U.S.) dominated the overactive bladder treatment market and accounted for approximately 60% to 70% share of the overall market.
Astellas Pharma, Inc. dominated the global overactive bladder treatment market in 2016. The company offers two patented drugs, namely, VESIcare (solifenacin) and BETMIGA (mirabegron) in the market. VESIcare is the blockbuster drug offered by the company to maintain its leadership position in the overactive bladder treatment market owing to its high efficacy as compared to other oral treatments. Astellas’ “Creating Innovation” strategy, backed by its R&D wing, helps identify new therapeutic areas as well as new solutions for existing areas. Its robust pipeline is a result of high R&D investment over the years. As of April 2017, Astellas has 47 molecular and biological entities in the clinical pipeline.
Pfizer, Inc. held the second position in the global overactive bladder treatment market in 2016. Its blockbuster drugs—Detrol and Toviaz—have generated high revenues for the company in the overactive bladder treatment market. The company adopts an aggressive marketing strategy for OAB treatment products, “GottaGo” and “YourWay” are the prominent ones. Pfizer employed Mesmerize Marketing for an unbranded campaign, to drive traffic to its website, overactivebladder.com. The company also introduced a free 12-week program designed to help physicians educate patients on bladder overactivity. Pfizer is also a major innovator in the pharma industry with 96 projects in its pipeline.
Some of the other players competing in this market are Allergan, Plc. (Ireland), Teva Pharmaceutical Industries Limited (Israel), Mylan N.V. (U.S.), Medtronic plc (Ireland), Endo International plc (Ireland), and Sanofi (France).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
